[go: up one dir, main page]

WO2019035623A3 - Cancer diagnosis method using lectin-coupled nanoparticles - Google Patents

Cancer diagnosis method using lectin-coupled nanoparticles Download PDF

Info

Publication number
WO2019035623A3
WO2019035623A3 PCT/KR2018/009290 KR2018009290W WO2019035623A3 WO 2019035623 A3 WO2019035623 A3 WO 2019035623A3 KR 2018009290 W KR2018009290 W KR 2018009290W WO 2019035623 A3 WO2019035623 A3 WO 2019035623A3
Authority
WO
WIPO (PCT)
Prior art keywords
lectin
diagnosis method
cancer diagnosis
nanoparticles
coupled nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/009290
Other languages
French (fr)
Korean (ko)
Other versions
WO2019035623A2 (en
Inventor
최종훈
구형준
김교범
최용현
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Chung Ang University
Original Assignee
Industry Academic Cooperation Foundation of Chung Ang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Chung Ang University filed Critical Industry Academic Cooperation Foundation of Chung Ang University
Publication of WO2019035623A2 publication Critical patent/WO2019035623A2/en
Publication of WO2019035623A3 publication Critical patent/WO2019035623A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G01N2333/42—Lectins, e.g. concanavalin, phytohaemagglutinin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a method for diagnosing cancer by using lectin-coupled nanoparticles to detect exosomes, wherein the nanoparticles are capable of effectively detecting and separating exosomes secreted by cancer cells, and thus can be usefully applied to the diagnosis of cancer.
PCT/KR2018/009290 2017-08-14 2018-08-13 Cancer diagnosis method using lectin-coupled nanoparticles Ceased WO2019035623A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0103250 2017-08-14
KR20170103250 2017-08-14

Publications (2)

Publication Number Publication Date
WO2019035623A2 WO2019035623A2 (en) 2019-02-21
WO2019035623A3 true WO2019035623A3 (en) 2019-05-16

Family

ID=65362700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/009290 Ceased WO2019035623A2 (en) 2017-08-14 2018-08-13 Cancer diagnosis method using lectin-coupled nanoparticles

Country Status (2)

Country Link
KR (1) KR102095018B1 (en)
WO (1) WO2019035623A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102179001B1 (en) * 2019-04-22 2020-11-16 중앙대학교 산학협력단 Device for detecting the glycan and method of the same
CN114720683A (en) * 2022-05-20 2022-07-08 南京鼓楼医院 Preparation method and application of magnetic Janus microcarrier for bladder cancer exosome multivariate analysis
KR102865711B1 (en) * 2022-09-27 2025-09-26 중앙대학교 산학협력단 Marker capturing cancer diagnosis device and method for diagnosing cancer by market capturing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931303B1 (en) * 2008-12-12 2009-12-11 한국과학기술원 Microfluidic Chips for Fine Particle Alignment and Separation Using Inclined Substrates
US20160258940A1 (en) * 2013-10-18 2016-09-08 Imra America, Inc. Multifunctional metal nanostructure and method for producing same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2498094B1 (en) 2010-01-21 2016-02-24 J-Oil Mills, Inc. Method for detecting pancreatic cancer
KR101546076B1 (en) 2013-05-29 2015-08-20 전남대학교산학협력단 Rapid Methods for Detecting Hepatitis A Virus or Norovirus in a Sample Using a Magnetic Bead and Plant-Derived Lectins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931303B1 (en) * 2008-12-12 2009-12-11 한국과학기술원 Microfluidic Chips for Fine Particle Alignment and Separation Using Inclined Substrates
US20160258940A1 (en) * 2013-10-18 2016-09-08 Imra America, Inc. Multifunctional metal nanostructure and method for producing same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BELYANINA, IRINA V. ET AL.: "In Vivo Cancer Cells Elimination Guided by Aptamer-functionalized Gold-coated Magnetic Nanoparticles and Controlled with Low Freuency Alternating Magnetic Field", THERANOSTICS, vol. 7, no. 13, 30 July 2017 (2017-07-30), pages 3326 - 3337, XP055608779, ISSN: 1838-7640, DOI: 10.7150/thno.17089 *
BISWAS, AMIT KMNER ET AL.: "Nanotechnology Based Approaches in Cancer Therapeutics", ADVANCES IN NATURAL SCIENCES: NANOSCIENCE AND NANOTECHNOLOGY, vol. 5, no. 4, 4 November 2014 (2014-11-04), pages 043001, XP055608769, ISSN: 2043-6262, DOI: 10.1088/2043-6262/5/4/043001 *
CATARINA, ROMA-RODRIGUES ET AL.: "Tumor Microenvironment Modulation via Gold Nanoparticles Targeting Malicious Exosomes: Implications for Cancer Diagnostics and Therapy", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 18, no. 1, 14 January 2017 (2017-01-14), pages 162, XP055608772, ISSN: 1422-0067, DOI: 10.3390/ijms18010162 *
HE, XIUXIA ET AL.: "Lectin-conjugated Fe203@Au Core@shell Nanoparticles as Dual Mode Contrast Agents for in Vivo Detection of Tumor", MOLECULAR PHARMACEUTICS, vol. 11, no. 3, 28 January 2014 (2014-01-28), pages 738 - 745, XP055608760, ISSN: 1543-8384, DOI: 10.1021/mp400456j *
LI, PIN ET AL.: "Progress in Exosome Isolation Techniques", THERANOSTICS, vol. 7, no. 3, 26 January 2017 (2017-01-26), pages 789 - 804, XP055417509, DOI: doi:10.7150/thno.18133 *
PRAMOD KS, THAKUR S ET AL.: "Utilization of Polymeric Nanoparticle in Cancer Treatment: a Review", JOURNAL OF PHARMACEUTICAL CARE & HEALTH SYSTEMS, vol. 4, no. 2, 21 April 2017 (2017-04-21), pages 1000172, XP055608774, ISSN: 2376-0419, DOI: 10.4172/2376-0419.1000172 *

Also Published As

Publication number Publication date
KR20190018395A (en) 2019-02-22
WO2019035623A2 (en) 2019-02-21
KR102095018B1 (en) 2020-03-30

Similar Documents

Publication Publication Date Title
WO2014187959A3 (en) Lung cancer diagnostic method and means
MY194686A (en) Detection of chromosome interactions
WO2016207717A8 (en) Anti-vista antibodies and fragments
PL3523639T3 (en) Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same
AR090973A1 (en) USEFUL ANTIBODIES FOR CANCER DIAGNOSIS
EP3194624A4 (en) Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor
WO2014116833A3 (en) Compositions and methods for detecting neoplasia
FI20155280A7 (en) Prognostic and diagnostic glycan-based biomarkers of brain damage
NZ629555A (en) Monocyte biomarkers for cancer detection
EA201500080A1 (en) METHOD IN VITRO DIAGNOSIS AND MONITORING OF CANCER
WO2015049289A3 (en) Breast cancer diagnostic method and means
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
MX358474B (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases.
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
EP4513187A3 (en) Methods of detecting prostate cancer
MX2015015452A (en) Method and system for assessing health condition.
WO2015153948A3 (en) Microtentacle imaging in patient tumor samples
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
EP3292218A4 (en) Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
WO2019035623A3 (en) Cancer diagnosis method using lectin-coupled nanoparticles
EP4428251A3 (en) Methods of detecting prostate cancer
EP4283304A3 (en) Methods of detecting anti-leptin neutralizing antibodies
EP3187106A4 (en) Blood pressure measuring auxiliary device, blood pressure measuring device, and design method therefor
MX363679B (en) Method of diagnosing cancer.
WO2014008273A3 (en) Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18846092

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18846092

Country of ref document: EP

Kind code of ref document: A2